The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 25, 2021

Filed:

May. 31, 2018
Applicant:

Arcturus Therapeutics, Inc., San Diego, CA (US);

Inventors:

Pattraranee Limphong, San Diego, CA (US);

Carlos G. Perez-Garcia, San Diego, CA (US);

Kiyoshi Tachikawa, San Diego, CA (US);

Padmanabh Chivukula, San Diego, CA (US);

Arisa Cale, San Diego, CA (US);

Angel I-Jou Leu, San Diego, CA (US);

Jared Davis, San Diego, CA (US);

Assignee:

Arcturus Therapeutics, Inc., San Diego, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/52 (2006.01); C12N 15/82 (2006.01); C07K 14/805 (2006.01); C07K 14/775 (2006.01); C07K 14/75 (2006.01); C07K 14/47 (2006.01); C07K 14/415 (2006.01); C07K 14/505 (2006.01); A61K 38/01 (2006.01); A61K 38/17 (2006.01); A61K 38/42 (2006.01); A61K 38/36 (2006.01); A61K 38/18 (2006.01);
U.S. Cl.
CPC ...
C12N 15/8257 (2013.01); C07K 14/415 (2013.01); C07K 14/472 (2013.01); C07K 14/4717 (2013.01); C07K 14/505 (2013.01); C07K 14/75 (2013.01); C07K 14/775 (2013.01); C07K 14/805 (2013.01); C12N 15/52 (2013.01); A61K 38/012 (2013.01); A61K 38/1725 (2013.01); A61K 38/18 (2013.01); A61K 38/363 (2013.01); A61K 38/42 (2013.01);
Abstract

This invention provides expressible polynucleotides, which can express a target protein or polypeptide. Synthetic mRNA constructs for producing a protein or polypeptide can contain one or more 5' UTRs, where a 5′ UTR may be expressed by a gene of a plant. In some embodiments, a 5′ UTR may be expressed by a gene of a member ofgenus. The synthetic mRNA constructs can be used as pharmaceutical agents for expressing a target protein or polypeptide in vivo.


Find Patent Forward Citations

Loading…